Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF MAY 16, 2014 FBO #4556
SOLICITATION NOTICE

99 -- Service contract TCR sequencing Adaptive Biotechnologies

Notice Date

5/14/2014
 

Notice Type

Presolicitation
 

NAICS

541711 — Research and Development in Biotechnology
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
 

ZIP Code

20852
 

Solicitation Number

N02RC42535-83
 

Archive Date

6/12/2014
 

Point of Contact

Gwennifer K. Epps, Phone: 240-276-5445, Terry Galloway, Phone: 240-276-5384
 

E-Mail Address

eppsg@mail.nih.gov, gallowaytl@mail.nih.gov
(eppsg@mail.nih.gov, gallowaytl@mail.nih.gov)
 

Small Business Set-Aside

N/A
 

Description

The National Cancer Institute (NCI), Center for Cancer Research (CCR), Surgery Branch (SB) plans to procure on a sole source basis a service contract for 40,000 input genomes, and 200,000 TCR sequences survey which includes a DNA Extraction Fee and domestic shipping and handling, from Adaptive Biotechnologies, 1551 Eastlake Ave E #200, Seattle, WA 98102. This process will be processed in accordance with simplified acquisitions procedures as stated in FAR Part 13 13.106-1(b)(1) and is exempt for the requirements of FAR Part 6. The North American Industry Classification System code is 541711, and the business size standard is 500. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. Note: The period of performance has not been detemined at this time. The Surgery Branch of the National Cancer Institute has a dual function at the NIH. Investigators in the Branch are involved in the conduct of laboratory and clinical research aimed at improving the care, management, and outcome of patients with cancer. Important areas of laboratory research include tumor immunology, immunotherapy and gene therapy of solid tumors, epigenetic changes in pulmonary malignancies, tumor stem cells, and molecular changes in breast carcinogenesis. In these studies, an emphasis is placed on the translation of laboratory findings into the development of clinical protocols. Clinical efforts emphasize the development of new approaches to the immunotherapy of cancer, to the diagnostic and prognostic evaluation of solid tumors, as well as the development of innovative surgical and adjunctive approaches to the treatment of patients with primary and metastatic cancer. T cells express a T cell receptor (TCR) on the cell surface that determines their specificity. A TCR is created by selecting and splicing together a single V, D and J segment from a collection of available genomic segments. At the junctions between V-D and D-J segments, a varying number of nucleotides are deleted and a special enzyme inserts random nucleotides, creating a unique TCR. It is these inserted nucleotides that are responsible for the vast diversity found in the human TCR repertoire. T cell receptor immune-profiling can be used to monitor T cell responses to a given immune challenge even without the knowledge of the specific epitope targeted. NCI is particularly interested in performing TCR sequencing from T cell populations isolated from human tumor samples. In the tumors, T cells are exposed to tumor antigens, and the frequency of a specific TCR clono type could be indicative of its ability to recognize the tumor. Thus, the study of the intra tumoral T cell repertoire may lead to novel ways to rapidly identify and isolate TCRs that can be used to treat patients with cancer. The technology necessary to sequence the hyper variable region of the TCR involves a multiplex PCR with a mixture of primers targeting the rearranged variable and joining segments to capture receptor diversity. Differential hybridization kinetics can introduce significant amplification biases that alter the composition of sequence libraries and potentially biasing the data obtained. To identify and minimize such biases Adaptive Biotechnologies uses a synthetic immune receptor repertoire, which enables the computational removal residual bias after sequencing. Adaptive Biotechnologies has invented a patent-pending technology that utilizes advances in high-throughput sequencing and a state-of-the-art computer infrastructure to provide researchers in-depth analysis of the T-cell receptor repertoire. With this technology, scientists are able to identify the exact makeup of approximately 10-15 million unique TCRs in one individual, compared to previous techniques that could catalog only about 30,000. In addition to the qualifications of Adaptive to perform this service they provide their service at a highly competitive price. Finally, TCR deep sequencing is a relatively new and evolving technology and Adaptive Biotechnologies has pioneered this technology and made it commercially available. Adaptive Biotechnologies has 6+ years of a proven track record, including a growing list of clients, and their services have resulted in the publication of numerous articles in peer reviewed scientific journals, and has works in close contact with the Surgery Branch in providing state-of-the-art technology and superior serving. No other company provides the services provided by Adaptive Biotechnologies, including TCR sequencing and personalized analysis adapted to each project at such a competitive price. NCI has been working with Adaptive technologies and have performed some control experiments to test their technology, even with low starting cell number (<10,000), and have received accurate results back. Thus, the results provided by Adaptive Biotechnologies have proven to be reliable, and give NCI confidence to proceed using their technology. Finally, the service contract provided by Adaptive Biotechnologies will provide the necessary tools NCI needs to study the TCR repertoire of intratumoral T cell subsets and may help NCI identify and isolate tumor-specific T cell receptors. Adaptive Biotechnologies has exclusively in-licensed a patent family from the FHRCR called "A Method of Measuring Adaptive Immunity. This patent provides exclusive access to the proprietary sequencing technology developed by Harlan Robins and Chris Carlson at the FHCRC. Adaptive has an 11 step sample preparation methodology which goes way beyond competition to standardize the template (genetic material) that is loaded onto the sequencer. In addition, Adaptive has written seven propriety software programs that "clean the data" after it comes off the sequencer. These steps remove bias, correct errors, and have other quality control mechanisms built in. Thus based on this information Adaptive Biotechnologies is the only known source for this service. This is not a solicitation for competitive quotations. However, if any interested party especially small business, believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on, May 28, 2014. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (240) 276-5401 or emailed to Gwennifer Epps, Contracting Officer at eppsg@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC42535-83 on all correspondence.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC42535-83/listing.html)
 

Place of Performance

Address: Building 10, Clinical Research Center, Bethesda, Maryland, 20814, United States

Zip Code: 20814
 

Record

SN03365500-W 20140516/140514234211-14ccef4a70a46ff87b68ec7c0d9dc267 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |